Transgene S.a.

Transgene

Claude Sene

Yves Cordier

Daniel Malarme

Didier Lamy

Sylvie Campourcy

Mélina Chasle

Melina Chasle

The present invention relates to formulation comprising (i) at least one virus-based material, (ii) at least one polymer selected in the group of polyvinylpyrrolidone and derivatives thereof, (iii) at least one sugar, (iv) at least two different amino acids, (v) at least two pharmaceutical acceptable salts, wherein at least one of said salts is a phosphate salt and, optionally (vi) a pharmaceutical acceptable buffer. Such a formulation is particularly suitable for freeze-drying. The present invention also relates to the corresponding dry product, as well as its preparation process. The present invention also relates to a reconstituted material comprising said dry product, which can be administered to a patient in need thereof. Such formulation and reconstituted material are useful as vaccines, preferably for the treatment and/or the prevention of cancers, infectious diseases and/or autoimmune disorders.

Virus-containing formulation and use thereof

The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.

Process for producing poxviruses and poxvirus compositions

The present invention relates to a method for producing and purifying a wild type, an attenuated and/or a recombinant Orthopoxvirus. The present invention relates to a purified wild type, attenuated and/or recombinant Orthopoxvirus obtained by the method of the invention and to a pharmaceutical composition, preferably a vaccine, comprising said purified Orthopoxvirus for the treatment and/or the prevention a cancer, an infectious disease and/or an autoimmune disorder, and uses thereof. The present invention also relates to the use of an immortalized avian cell line obtained from an avian cell belonging to the Anatidae family, in particularimmortalized avian cell lines comprising a nucleic acid sequence coding a telomerase reverse transcriptase (TERT) and optionally an E1A nucleic acid sequence, for the production of a wild type, attenuated and/or recombinant Orthopoxvirus according to the process of the invention.

Method for orthopoxvirus production and purification

A method for preparing a viral aerosol from a dilute viral suspension prepared by dissolving a virus in an aqueous solution containing 6-12 g/l of a monovalent cation salt, or 50-100 g/l of a hexose, which is then nebulized with a gas pressure of 0.5-3.5 bars or an ultrasonic frequency of 2-5 MHz. The resulting aerosol composition is also disclosed.

Method for preparing a viral aerosol

The present invention provides a novel method for preserving infectious recombinant viruses in frozen or liquid form, in which infectious viruses are preserved in an aqueous solution. The recombinant virus suspension comprises an aqueous sucrose solution at a concentration of 0.75 M or above, preferably between 0.75 M and 1.5 M, or more preferably at a concentration of 1 M. The preserved aqueous viral suspension further provides a medicament that can be used therapeutically or prophylactically for the treatment of a human or animal body by gene therapy.

Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicine

A method of preparing a viral aerosol from a dilute viral suspension prepared by dissolving a virus in an aqueous solution containing 6-12 g/l of a monovalent cation salt, or 50-100 g/l of a hexose, which is then nebulised with a gas pressure of 0.5-3.5 bars or an ultrasonic frequency of 2-5 MHZ. The resulting aerosol composition is also disclosed.

Growing community of inventors

Strasbourg, France

Claude Sene